Nuclear Medicine and Radiopharmaceutic-United States Market Status and Trend Report 2013-2023
Report Summary
Nuclear Medicine and Radiopharmaceutic-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nuclear Medicine and Radiopharmaceutic industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Nuclear Medicine and Radiopharmaceutic 2013-2017, and development forecast 2018-2023
Main market players of Nuclear Medicine and Radiopharmaceutic in United States, with company and product introduction, position in the Nuclear Medicine and Radiopharmaceutic market
Market status and development trend of Nuclear Medicine and Radiopharmaceutic by types and applications
Cost and profit status of Nuclear Medicine and Radiopharmaceutic, and marketing status
Market growth drivers and challenges
The report segments the United States Nuclear Medicine and Radiopharmaceutic market as:
United States Nuclear Medicine and Radiopharmaceutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Nuclear Medicine and Radiopharmaceutic Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic Radioisotopes
Therapeutic Radioisotopes
United States Nuclear Medicine and Radiopharmaceutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Cardiology
Others
United States Nuclear Medicine and Radiopharmaceutic Market: Players Segment Analysis (Company and Product introduction, Nuclear Medicine and Radiopharmaceutic Sales Volume, Revenue, Price and Gross Margin):
Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Nuclear Medicine and Radiopharmaceutic-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nuclear Medicine and Radiopharmaceutic industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Nuclear Medicine and Radiopharmaceutic 2013-2017, and development forecast 2018-2023
Main market players of Nuclear Medicine and Radiopharmaceutic in United States, with company and product introduction, position in the Nuclear Medicine and Radiopharmaceutic market
Market status and development trend of Nuclear Medicine and Radiopharmaceutic by types and applications
Cost and profit status of Nuclear Medicine and Radiopharmaceutic, and marketing status
Market growth drivers and challenges
The report segments the United States Nuclear Medicine and Radiopharmaceutic market as:
United States Nuclear Medicine and Radiopharmaceutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Nuclear Medicine and Radiopharmaceutic Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diagnostic Radioisotopes
Therapeutic Radioisotopes
United States Nuclear Medicine and Radiopharmaceutic Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Oncology
Cardiology
Others
United States Nuclear Medicine and Radiopharmaceutic Market: Players Segment Analysis (Company and Product introduction, Nuclear Medicine and Radiopharmaceutic Sales Volume, Revenue, Price and Gross Margin):
Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF HIGH POTENCY API
1.1 Definition of High Potency API in This Report
1.2 Commercial Types of High Potency API
1.2.1 Synthetic HPAPIs
1.2.2 Biotech HPAPIs
1.3 Downstream Application of High Potency API
1.3.1 Oncology
1.3.2 Hormonal Disorders
1.3.3 Glaucoma
1.3.4 Other
1.4 Development History of High Potency API
1.5 Market Status and Trend of High Potency API 2013-2023
1.5.1 Global High Potency API Market Status and Trend 2013-2023
1.5.2 Regional High Potency API Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of High Potency API 2013-2017
2.2 Production Market of High Potency API by Regions
2.2.1 Production Volume of High Potency API by Regions
2.2.2 Production Value of High Potency API by Regions
2.3 Demand Market of High Potency API by Regions
2.4 Production and Demand Status of High Potency API by Regions
2.4.1 Production and Demand Status of High Potency API by Regions 2013-2017
2.4.2 Import and Export Status of High Potency API by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of High Potency API by Types
3.2 Production Value of High Potency API by Types
3.3 Market Forecast of High Potency API by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of High Potency API by Downstream Industry
4.2 Market Forecast of High Potency API by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HIGH POTENCY API
5.1 Global Economy Situation and Trend Overview
5.2 High Potency API Downstream Industry Situation and Trend Overview
CHAPTER 6 HIGH POTENCY API MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of High Potency API by Major Manufacturers
6.2 Production Value of High Potency API by Major Manufacturers
6.3 Basic Information of High Potency API by Major Manufacturers
6.3.1 Headquarters Location and Established Time of High Potency API Major Manufacturer
6.3.2 Employees and Revenue Level of High Potency API Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HIGH POTENCY API MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative High Potency API Product
7.1.3 High Potency API Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Novartis International
7.2.1 Company profile
7.2.2 Representative High Potency API Product
7.2.3 High Potency API Sales, Revenue, Price and Gross Margin of Novartis International
7.3 Sanofi
7.3.1 Company profile
7.3.2 Representative High Potency API Product
7.3.3 High Potency API Sales, Revenue, Price and Gross Margin of Sanofi
7.4 Boehringer Ingelheim
7.4.1 Company profile
7.4.2 Representative High Potency API Product
7.4.3 High Potency API Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.5 Bristol-Myers Squibb
7.5.1 Company profile
7.5.2 Representative High Potency API Product
7.5.3 High Potency API Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.6 Teva Pharmaceutical
7.6.1 Company profile
7.6.2 Representative High Potency API Product
7.6.3 High Potency API Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical
7.7 Eli Lilly and Company
7.7.1 Company profile
7.7.2 Representative High Potency API Product
7.7.3 High Potency API Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.8 GlaxoSmithKline
7.8.1 Company profile
7.8.2 Representative High Potency API Product
7.8.3 High Potency API Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.9 Merck & Co
7.9.1 Company profile
7.9.2 Representative High Potency API Product
7.9.3 High Potency API Sales, Revenue, Price and Gross Margin of Merck & Co
7.10 AbbVie
7.10.1 Company profile
7.10.2 Representative High Potency API Product
7.10.3 High Potency API Sales, Revenue, Price and Gross Margin of AbbVie
7.11 Johnson & Johnson
7.11.1 Company profile
7.11.2 Representative High Potency API Product
7.11.3 High Potency API Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.12 Bayer
7.12.1 Company profile
7.12.2 Representative High Potency API Product
7.12.3 High Potency API Sales, Revenue, Price and Gross Margin of Bayer
7.13 Mylan
7.13.1 Company profile
7.13.2 Representative High Potency API Product
7.13.3 High Potency API Sales, Revenue, Price and Gross Margin of Mylan
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HIGH POTENCY API
8.1 Industry Chain of High Potency API
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HIGH POTENCY API
9.1 Cost Structure Analysis of High Potency API
9.2 Raw Materials Cost Analysis of High Potency API
9.3 Labor Cost Analysis of High Potency API
9.4 Manufacturing Expenses Analysis of High Potency API
CHAPTER 10 MARKETING STATUS ANALYSIS OF HIGH POTENCY API
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of High Potency API in This Report
1.2 Commercial Types of High Potency API
1.2.1 Synthetic HPAPIs
1.2.2 Biotech HPAPIs
1.3 Downstream Application of High Potency API
1.3.1 Oncology
1.3.2 Hormonal Disorders
1.3.3 Glaucoma
1.3.4 Other
1.4 Development History of High Potency API
1.5 Market Status and Trend of High Potency API 2013-2023
1.5.1 Global High Potency API Market Status and Trend 2013-2023
1.5.2 Regional High Potency API Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of High Potency API 2013-2017
2.2 Production Market of High Potency API by Regions
2.2.1 Production Volume of High Potency API by Regions
2.2.2 Production Value of High Potency API by Regions
2.3 Demand Market of High Potency API by Regions
2.4 Production and Demand Status of High Potency API by Regions
2.4.1 Production and Demand Status of High Potency API by Regions 2013-2017
2.4.2 Import and Export Status of High Potency API by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of High Potency API by Types
3.2 Production Value of High Potency API by Types
3.3 Market Forecast of High Potency API by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of High Potency API by Downstream Industry
4.2 Market Forecast of High Potency API by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HIGH POTENCY API
5.1 Global Economy Situation and Trend Overview
5.2 High Potency API Downstream Industry Situation and Trend Overview
CHAPTER 6 HIGH POTENCY API MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of High Potency API by Major Manufacturers
6.2 Production Value of High Potency API by Major Manufacturers
6.3 Basic Information of High Potency API by Major Manufacturers
6.3.1 Headquarters Location and Established Time of High Potency API Major Manufacturer
6.3.2 Employees and Revenue Level of High Potency API Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HIGH POTENCY API MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Pfizer
7.1.1 Company profile
7.1.2 Representative High Potency API Product
7.1.3 High Potency API Sales, Revenue, Price and Gross Margin of Pfizer
7.2 Novartis International
7.2.1 Company profile
7.2.2 Representative High Potency API Product
7.2.3 High Potency API Sales, Revenue, Price and Gross Margin of Novartis International
7.3 Sanofi
7.3.1 Company profile
7.3.2 Representative High Potency API Product
7.3.3 High Potency API Sales, Revenue, Price and Gross Margin of Sanofi
7.4 Boehringer Ingelheim
7.4.1 Company profile
7.4.2 Representative High Potency API Product
7.4.3 High Potency API Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.5 Bristol-Myers Squibb
7.5.1 Company profile
7.5.2 Representative High Potency API Product
7.5.3 High Potency API Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.6 Teva Pharmaceutical
7.6.1 Company profile
7.6.2 Representative High Potency API Product
7.6.3 High Potency API Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical
7.7 Eli Lilly and Company
7.7.1 Company profile
7.7.2 Representative High Potency API Product
7.7.3 High Potency API Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.8 GlaxoSmithKline
7.8.1 Company profile
7.8.2 Representative High Potency API Product
7.8.3 High Potency API Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.9 Merck & Co
7.9.1 Company profile
7.9.2 Representative High Potency API Product
7.9.3 High Potency API Sales, Revenue, Price and Gross Margin of Merck & Co
7.10 AbbVie
7.10.1 Company profile
7.10.2 Representative High Potency API Product
7.10.3 High Potency API Sales, Revenue, Price and Gross Margin of AbbVie
7.11 Johnson & Johnson
7.11.1 Company profile
7.11.2 Representative High Potency API Product
7.11.3 High Potency API Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.12 Bayer
7.12.1 Company profile
7.12.2 Representative High Potency API Product
7.12.3 High Potency API Sales, Revenue, Price and Gross Margin of Bayer
7.13 Mylan
7.13.1 Company profile
7.13.2 Representative High Potency API Product
7.13.3 High Potency API Sales, Revenue, Price and Gross Margin of Mylan
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HIGH POTENCY API
8.1 Industry Chain of High Potency API
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HIGH POTENCY API
9.1 Cost Structure Analysis of High Potency API
9.2 Raw Materials Cost Analysis of High Potency API
9.3 Labor Cost Analysis of High Potency API
9.4 Manufacturing Expenses Analysis of High Potency API
CHAPTER 10 MARKETING STATUS ANALYSIS OF HIGH POTENCY API
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
